Why the study?
Does TNF inhibition improve the clinical course in patients with heart failure?
Does TNF inhibition improve the clinical course in patients with heart failure?
This review highlights that despite the pathophysiological role of TNF in cardiac stress, TNF inhibition does not appear to benefit patients with heart failure.
TNF inhibition should not be pursued in heart failure; confirms controlled studies and leaves open alternative anti-inflammatory targets.
Tumor necrosis factor (TNF) is a proinflammatory cytokine that can produce widespread deleterious effects when expressed in large amounts. It is produced in the heart by both cardiac myocytes and resident macrophages under conditions of cardiac stress, and is thought to be responsible for many of the untoward manifestations of cardiac disease. This article discusses the role of TNF in heart disease and some potential therapeutic modalities that can influence the cytokine activity. The results of controlled studies would suggest that TNF inhibition does not influence the clinical course of patients with heart failure.
No takes yet. Share an insight, caveat, or question.
Retter et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: